AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03788915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online dietetic lifestyle counseling
Description: The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen).
Study NCT03788915 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
Study NCT04022824 — intervention group
Intervention type: OTHER
Intervention: OSA
Description: Patients with OSA (apnea hypopnea index ≥15) based on sleep study
Study NCT04022824 — intervention group
Intervention type: OTHER
Intervention: Non-OSA
Description: Patients without OSA (apnea hypopnea index \<15) based on sleep study
Study NCT02605213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin for treatment of primary sclerosing cholangitis
Study NCT02605213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for control Group of primary sclerosing vhlangitis
Study NCT03321994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stereotaxic unit, navigation
Description: CT-guided needle guidance using stereotaxic unit, navigation
Study NCT03321994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional biopsy technique
Description: CT-guided needle guidance using conventional biopsy technique
Study NCT01682148 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Study NCT01682148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Study NCT03265184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green coffee extract
Description: Patients in treatment group take 400 mg GCE supplements twice a day for tow month
Study NCT03014167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: All eligible individuals will receive a single dose of 400 mg albendazole.
Study NCT03265184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green coffee extract
Description: Patients in treatment group take 400 mg GCE supplements twice a day for tow month
Study NCT03014167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: All eligible individuals will receive a single dose of 400 mg albendazole.
Study NCT01058850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rindopepimut
Description: 250 or 500 mcg; intradermal injection
Study NCT00003525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT02987738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: two administrations in the evening and 12 hours later
Study NCT02987738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: two administrations in the evening and 12 hours later
Study NCT04026152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
Study NCT04026152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
Study NCT04026152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
Study NCT00678587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: 75 mg, once daily, oral
Study NCT04543851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARA - carbon fibre adjustable re-usable accessory for breast positioning
Description: Breast positioning to alleviate infra-mammary fold and lateral breast sag
Study NCT00678587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, once daily, oral
Study NCT05837078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge splitting with implant placement
Description: ridge splitting of mandibular denture followed by two implant placement
Study NCT01975779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A1: Lu AE58054 or placebo
Description: One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
Study NCT06749171 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting
Description: ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)
Study NCT02561962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 224
Description: Administered as an IV infusion.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo on days 1-5 of bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Leg Movement (PLM)
Description: Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Leg Movement (PLM)
Description: Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar flexion
Description: Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plantar flexion
Description: Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor test
Description: Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isometric knee extensor test
Description: Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Participants will undergo 5 days bed rest after 5 day baseline assessments
Study NCT01975779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort A2: Lu AE58054 or placebo
Description: One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
Study NCT01975779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort B1: Lu AE58054
Description: Two single oral doses 60 mg with >=7 days washout.
Study NCT02167841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knee-Chest Position
Study NCT04351113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bed rest
Description: Participants will undergo 5 days bed rest after 5 day baseline assessments
Study NCT00995150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG20
Description: levonorgestrel-releasing intrauterine system for contraception
Study NCT00995150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: Mirena intrauterine system
Study NCT01326130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic care management 1-6
Description: 1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
Study NCT01291563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
Study NCT01291563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: 8 tablets of TMC207 (100 mg/tablet) on Day 1
Study NCT01291563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMC207 placebo
Description: 8 tablets of TMC207 placebo on Day 1
Study NCT01291563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: 1 capsule of moxifloxacin placebo on Day 2
Study NCT03289611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sFlt-1 / PlGF ratio
Description: * Ambulatory management if sFlt-1 / PlGF ratio is below 38~* usual management if sFlt-1/PlGF is between 38 and 85.~* If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
Study NCT04415086 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: convalescent plasma
Description: The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
Study NCT04415086 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: convalescent plasma
Description: The study will be interrupted if the efficacy of the convalescent plasma group is proven, so that all severely ill patients as defined in the study can receive the convalescent plasma treatment. The same will occur if there is no difference in primary outcome with the use of convalescent plasma or serious adverse effects.
Study NCT01551433 — intervention group
Intervention type: DEVICE
Intervention: wireless pulse oximeter (Wipox)
Description: In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
Study NCT02398565 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00005772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Induced hypothermia
Description: Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
Study NCT00005772 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group: standard care
Study NCT00043082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: intravenous q 4 weeks
Study NCT00043082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: intravenous q 4 weeks
Study NCT00043082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: intravenous q 4 weeks
Study NCT00891176 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenitorixTM
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study NCT00891176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenitorixTM
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study NCT00891176 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study NCT00891176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
Study NCT04217434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 400 µm fibre length will be used in continuous contact mode
Description: Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given.
Study NCT04217434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 400 µm fibre length will be used in pulsed contact mode
Description: Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given.
Study NCT04217434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 300 µm fibre length will be used in continuous mode
Description: Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given.
Study NCT04217434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 300 µm fibre length will be used in pulsed contact mode
Description: Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given.
Study NCT03676387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided
Description: Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes.
Study NCT02323711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate
Description: If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
Study NCT02969447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of 10 units of intra venous oxytocin after fetal expulsion
Study NCT03699631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
Study NCT03699631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
Study NCT03699631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
Study NCT04264455 — intervention group
Intervention type: DEVICE
Intervention: Biomonitor
Description: Patients receive a Biomonitor only